Pathomechanism characterization and potential therapeutics identification for SCA3 targeting neuroinflammation

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Spinocerebellar ataxias (SCAs) are neurodegenerative diseases linked to expanded polyglutamine (polyQ) tracts.
• PolyQ protein misfolding causes oxidative stress and inflammation, exacerbating neurotoxicity.
• Neuroinflammation, indicated by activated microglia, is implicated in SCA pathogenesis, particularly in SCA type 3 (SCA3).

Purpose of the Study:

• To evaluate the anti-inflammatory effects of four novel compounds: NC009-1, AM404, VB-037, and LM-031.
• To assess their potential in mitigating neuroinflammation and cellular damage in SCA3 models.
• To explore their impact on polyglutamine aggregation and oxidative stress.

Main Methods:

• Tested compounds on human HMC3 microglia and SCA3 patient-derived SH-SY5Y cells.
• Assessed inflammatory markers (NO, IL-1β, TNF-α, IL-6, CD68) in activated microglia.
• Evaluated effects on caspase 1 activity, lactate dehydrogenase release, polyQ aggregation, and reactive oxygen species (ROS) in neuronal cells.
• Analyzed key inflammatory signaling pathways (IκBα/P65, JNK/JUN, P38/STAT1).

Main Results:

• All four compounds suppressed inflammatory mediators (NO, IL-1β, TNF-α, IL-6) and CD68 expression in activated microglia.
• Compounds reduced caspase 1 activity and lactate dehydrogenase release in inflamed neuronal cells.
• Treatment decreased polyQ aggregation and ROS levels, while promoting neurite outgrowth.
• Compounds inhibited key inflammatory signaling pathways, including NF-κB, JNK, and p38 MAPK.

Conclusions:

• NC009-1, AM404, VB-037, and LM-031 exhibit significant anti-inflammatory and neuroprotective properties.
• These compounds demonstrate potential for treating SCA3 by targeting neuroinflammation and polyQ pathology.
• The findings suggest broader applicability for polyQ diseases.